Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Supreme Court Allowing New Prempro Trial

By Drug Discovery Trends Editor | June 21, 2010

WASHINGTON (AP) – The Supreme Court is allowing a new trial in the case of a woman who got breast cancer after taking hormone replacement therapy and is seeking punitive damages against Wyeth Pharmaceuticals.

The justices on Monday rejected Wyeth’s attempt to block the trial because it is to be limited to punitive damages. Wyeth also wanted the high court to throw out $2.75 million compensatory damages that the woman, Donna Scroggin of Little Rock, Ark., won after suing Wyeth and Upjohn Co., another drugmaker.

Both companies now are owned by Pfizer Inc.

A jury also awarded Scroggin $27 million in punitive damages after concluding that Wyeth inadequately warned her that its drugs Premarin and Prempro carried an increased risk of breast cancer.

A federal judge struck down the punitive damages award, saying certain testimony from former Food and Drug Administration official Dr. Suzanne Parisian, who was the plaintiff’s regulatory expert, shouldn’t have been allowed at trial.

The 8th U.S. Circuit Court of Appeals in St. Louis ordered the partial retrial, limited to punitive damages.

“We continue to believe that Wyeth and Pharmacia & Upjohn acted responsibly by conducting or supporting more than 180 studies on hormone therapy’s benefits and risks, keeping the U.S. Food and Drug Administration (FDA) fully informed, and providing proper, accurate and science-based information to patients and doctors,” Pfizer said in a statement.

Chief Justice John Roberts, who owns Pfizer stock, did not take part in the consideration of the case.

The case is Wyeth v. Scroggin, 09-1123.

Date: June 21, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50